In this article we will discuss Olaparib (Description-9)
Author: priyeshbanerjeept
Physiotherapist, Certified MFR therapist on a mission to provide one stop search destination for various diseases its symptoms,causes,diagnosis,treatment, physiotherapy management,rehabilitation with practical examples for aspiring physiotherapists,medical professionals and general public.
In this article, we will discuss Olaparib (Description-8). So, let’s get started. Metabolism In vitro, CYP3A4/5 were shown to be the enzymes primarily responsible for the metabolism of Olaparib. Following oral dosing of 14C-olaparib to female patients, unchanged Olaparib accounted for the majority of the circulating radioactivity in plasma (70%). It was extensively metabolized with […]
In this article, we will discuss Olaparib (Description-7). So, let’s get started. Distribution Olaparib had a mean (± standard deviation) apparent volume of distribution of 158 ± 136 L after a single 300 mg dose of olaparib. The in vitro protein binding of olaparib is approximately 82%
In this article, we will discuss Olaparib (Description-6). So, let’s get started. Co-administration of a high fat meal with Olaparib slowed the rate (tmax delayed by 2.5 hours) of absorption, but did not significantly alter the extent of Olaparib absorption (mean AUC increased by approximately 8%).
In this article, we will discuss Olaparib (Description-5). So, let’s get started. (Absorption-2) Systemic exposure (single dose AUC) to olaparib increases approximately proportionally with doses over the dose range of 25 mg to 450 mg, Cmax increased slightly less than proportionally for the same dose range.